Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/29376
Başlık: Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac
Yazarlar: Sudha, Thangirala
Bharali, Dhruba J
Darwish, Noureldien H.E.
Keating, Kelly A
Lin, Hung-Yun
Davis, Paul J.
Mousa, Shaker A
Uludağ Üniversitesi/Veteriner Fakültesi/Fizyoloji Anabilim Dalı.
Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.
0000-0002-5600-8162
Yalçın, Murat
Coşkun, Melis Debreli
AAG-6956-2021
AAF-3992-2020
57192959734
57193066146
Anahtar kelimeler: Biotechnology & applied microbiology
Science & technology - other topics
Cisplatin
Integrin
Nanotetrac
NDAT
Tetraiodothyroacetic acid
Urinary bladder carcinoma
Activated protein-kinase
Tetraiodothyroacetic acid
Thyroid-hormone
Cancer-cells
Platinum
Integrin
Receptor
Growth
Drugs
Yayın Tarihi: Şub-2017
Yayıncı: Future Medicine
Atıf: Sudha, T. vd. (2017). ''Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac''. Nanomedicine, 12(3), 195-205.
Özet: Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin alpha v beta 3; alpha v beta 3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.
URI: https://doi.org/10.2217/nnm-2016-0315
https://www.futuremedicine.com/doi/10.2217/nnm-2016-0315
http://hdl.handle.net/11452/29376
ISSN: 1743-5889
1748-6963
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Yalçın_vd_2017.pdf3.13 MBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons